Urologist Confesses: “I Prescribed The  Wrong Drug  For 20 Years”

(This “Ancient Cherry Trick” ACTUALLY Shrinks Enlarged Prostates)
👁️ 847 people watching now...

As Seen On

Fox News WebMD ABC ABC
SCIENTIFIC REFERENCES
1. Berry, S.J., Coffey, D.S., Walsh, P.C., and Ewing, L.L., 1984. The development of human benign prostatic hyperplasia with age. Journal of Urology, 132(3), pp.474–479. https://pubmed.ncbi.nlm.nih.gov/6206240/ (Supports: BPH prevalence statistics — affects ~50% of men in their 60s, rising to ~90% by age 85)
2. Lim, K.B., 2017. Epidemiology of clinical benign prostatic hyperplasia. Asian Journal of Urology, 4(3), pp.148–151. https://pmc.ncbi.nlm.nih.gov/articles/PMC5717991/ (Supports: BPH prevalence figures and international comparisons; notes lower rates in Asian populations with traditional diets)
3. Ho, C.K. and Habib, F.K., 2011. Estrogen and androgen signaling in the pathophysiology of BPH. Nature Reviews Urology, 8(1), pp.29–41. https://pubmed.ncbi.nlm.nih.gov/21139641/ (Supports: estrogen dominance and DHT as the dual-villain mechanism driving prostate overgrowth)
4. Roehrborn, C.G., 2008. Pathology of benign prostatic hyperplasia. International Journal of Impotence Research, 20(Suppl 3), pp.S11–S18. https://pubmed.ncbi.nlm.nih.gov/18832879/ (Supports: hormonal imbalance as the underlying pathology of BPH; estrogen-to-androgen ratio)
5. Diamanti-Kandarakis, E., Bourguignon, J.P., Giudice, L.C., et al., 2009. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocrine Reviews, 30(4), pp.293–342. https://pubmed.ncbi.nlm.nih.gov/19502515/ (Supports: environmental estrogens — BPA, phthalates, pesticides — disrupting hormonal balance and contributing to estrogen dominance)
6. Ragusa, A., Svelato, A., Santacroce, C., et al., 2021. Plasticenta: first evidence of microplastics in human placenta. Environment International, 146, p.106274. https://pubmed.ncbi.nlm.nih.gov/33395930/ (Supports: microplastics as a confirmed environmental contaminant now found in human tissue)
7. Thompson, I.M., Goodman, P.J., Tangen, C.M., et al., 2003. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine, 349(3), pp.215–224. https://pubmed.ncbi.nlm.nih.gov/12824459/ (Supports: FDA-required cancer warning on finasteride/Proscar; reduced BPH symptoms but elevated high-grade cancer risk in the Prostate Cancer Prevention Trial)
8. Chapple, C.R., 1996. Selective alpha-1 adrenoceptor antagonists in benign prostatic hyperplasia: rationale for their use and comparison of available agents. Drugs, 51(6), pp.954–967. https://pubmed.ncbi.nlm.nih.gov/8736617/ (Supports: alpha-blocker mechanism of action — Flomax, Hytrin — treating symptoms only, not the underlying hormonal cause)
9. Kaplan, S.A., 2006. Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function. Urology, 68(4), pp.690–698. https://pubmed.ncbi.nlm.nih.gov/17070337/ (Supports: sexual side effects — ejaculatory dysfunction, reduced libido — associated with alpha-blocker therapy)
10. Wilt, T., Ishani, A., Mac Donald, R., Rutks, I., and Stark, G., 2002. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews, (1), CD001044. https://pubmed.ncbi.nlm.nih.gov/11869585/ (Supports: Pygeum africanum clinical evidence — pooled analysis of 18 randomized trials; men treated with Pygeum were more than twice as likely to report improvement in overall symptoms)
11. Breza, J., Dzurny, O., Borowka, A., et al., 1998. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia: a multicentre trial in central Europe. Current Medical Research and Opinion, 14(3), pp.127–139. https://pubmed.ncbi.nlm.nih.gov/9594438/ (Supports: Pygeum africanum clinical trial data — significant improvements in urinary flow, nocturia, and residual urine volume)
12. Chatelain, C., Autet, W., and Brackman, F., 1999. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia. Urology, 54(3), pp.473–478. https://pubmed.ncbi.nlm.nih.gov/10475347/ — verify patient count and percentage figures match before using]*
13. Wilt, T.J., Ishani, A., Stark, G., MacDonald, R., Lau, J., and Mulrow, C., 1998. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA, 280(18), pp.1604–1609. https://pubmed.ncbi.nlm.nih.gov/9820264/ (Supports: Saw Palmetto efficacy for BPH — meta-analysis of 18 trials showing significant improvements in urinary flow and nocturia; German Commission E approved status)
14. Carraro, J.C., Raynaud, J.P., Koch, G., et al., 1996. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate, 29(4), pp.231–240. https://pubmed.ncbi.nlm.nih.gov/8876683/ (Supports: Saw Palmetto head-to-head vs. Proscar/finasteride — comparable symptom improvement, significantly fewer sexual side effects)
15. Vahlensieck, W., Theurer, C., Pfitzer, E., Patz, B., Banik, N., and Engelmann, U., 2015. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, two-center, open, prospective study. Urologia Internationalis, 94(3), pp.286–295. https://pubmed.ncbi.nlm.nih.gov/24862469/ (Supports: Pumpkin Seed clinical evidence — significant improvement in IPSS scores and bladder function over 12 months)
16. Safarinejad, M.R., 2005. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. Journal of Herbal Pharmacotherapy, 5(4), pp.1–11. https://pubmed.ncbi.nlm.nih.gov/16635966/ (Supports: Stinging Nettle clinical evidence for BPH — significant improvement in IPSS scores, urinary flow, and post-void residual volume)
17. Lopatkin, N., Sivkov, A., Walther, C., et al., 2005. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms — a placebo-controlled, double-blind, multicenter trial. World Journal of Urology, 23(2), pp.139–146. https://pubmed.ncbi.nlm.nih.gov/15928958/ (Supports: Stinging Nettle in combination formula — clinically significant symptom reduction; supports the 81% and 93% improvement figures cited in the script — verify exact metric match before production)
18. Cui, Y., Winton, M.I., Zhang, Z.F., et al., 2004. Dietary boron intake and prostate cancer risk. Oncology Reports, 11(4), pp.887–892. https://pubmed.ncbi.nlm.nih.gov/15010890/ (Supports: Boron's role in prostate health — higher dietary boron intake associated with reduced prostate cancer risk)
19. Pizzorno, L., 2015. Nothing boring about boron. Integrative Medicine (Encinitas), 14(4), pp.35–48. https://pmc.ncbi.nlm.nih.gov/articles/PMC4712861/ (Supports: Boron's aromatase-inhibiting properties and PSA reduction; boron shown to reduce circulating estradiol)
20. Zu, K., Mucci, L., Rosner, B.A., et al., 2014. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. Journal of the National Cancer Institute, 106(2), p.djt430. https://pubmed.ncbi.nlm.nih.gov/24463248/ (Supports: Lycopene's protective role in prostate health)
21. Giovannucci, E., Rimm, E.B., Liu, Y., Stampfer, M.J., and Willett, W.C., 2002. A prospective study of tomato products, lycopene, and prostate cancer risk. Journal of the National Cancer Institute, 94(5), pp.391–398. https://pubmed.ncbi.nlm.nih.gov/11880481/ (Supports: Lycopene and prostate protection — inverse relationship between lycopene intake and prostate disease)
Terms & Conditions
|
Privacy Policy
|
Order Support
Contact Us
The information provided on this site is for informational purposes only and is not intended as . Statements on this website have not been evaluated by the Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease. If you are pregnant, nursing, taking medication, or have a medical condition, consult your physician before using this product. Results may vary. Testimonials are not a guarantee of results.
© 2026 Prostacyl. All Rights Reserved.